Cision PR Newswire

Ascletis’ Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with...

- ASC30 reduced HbA1c by a placebo-adjusted 1.7%, 1.6% and 1.7% from baseline for 40 mg, 60 mg and 80 mg, respectively, at 12 weeks, the...

CARsgen’s Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial

SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment...

Nature’s Miracle Holding, Inc. Announces Up to $29.7 Million Financing

ONTARIO, Calif., Jan. 13, 2025 /PRNewswire/ -- Nature's Miracle Holding, Inc. (Nasdaq: NMHI) ("Nature's Miracle"), a growing agriculture technology company providing equipment and services...

China Liberal Education Holdings Limited Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency

BEIJING, Jan. 13, 2025 /PRNewswire/ -- China Liberal Education Holdings Limited ("China Liberal" or the "Company") (NASDAQ: CLEU), a China-based company that provides technological consulting services...

Yiwu Brands Unite for Overseas Expansion with Grand Opening of Yiwu Selection Store

YIWU, China, Jan. 13, 2025 /PRNewswire/ -- Yiwu, the world's preeminent hub for small commodities, hosts an extensive trading network connecting the globe with...